Elaine Shum
NYU Langone Health
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Elaine Shum as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:33 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07874490 · Osimertinib and Cyclosporine A to Enhance Antitumor Efficacy in NSCLCNYU Langone Health · recruiting · Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor · principal investigator
- N/ANCT05164757 · Female Asian Nonsmoker Screening StudyNYU Langone Health · active not recruiting · Lung Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:33 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name in non-small cell lung cancer, ranked by citations from NIH iCite, fetched 2026-11-12 11:33 UTC. The ranking covers the 200 most relevant of 7 PubMed records, and a shared surname and initials can bring in a namesake. All 7 on PubMed
- Datopotamab Deruxtecan in Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study.J Clin Oncol · 2025126 citationsRCR 25.4
- Entinostat plus Pembrolizumab in Patients with Metastatic NSCLC Previously Treated with Anti-PD-(L)1 Therapy.Clin Cancer Res · 2021115 citationsRCR 5.4
- 64 citationsRCR 11.9
- A Pooled Analysis of Datopotamab Deruxtecan in Patients With EGFR-Mutated NSCLC.J Thorac Oncol · 202552 citationsRCR 9.6
- 25 citationsRCR 4.3
- First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations.N Engl J Med · 20267 citationsRCR 3.5
- Phase I/II Study of AXL-Specific Antibody-Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors.Cancer Res Commun · 20254 citationsRCR 0.7